CY1119445T1 - Αντισωματα εναντι του ανθρωπινου gdf8 - Google Patents

Αντισωματα εναντι του ανθρωπινου gdf8

Info

Publication number
CY1119445T1
CY1119445T1 CY20171101065T CY171101065T CY1119445T1 CY 1119445 T1 CY1119445 T1 CY 1119445T1 CY 20171101065 T CY20171101065 T CY 20171101065T CY 171101065 T CY171101065 T CY 171101065T CY 1119445 T1 CY1119445 T1 CY 1119445T1
Authority
CY
Cyprus
Prior art keywords
gdf8
antibodies against
against human
human gdf8
present
Prior art date
Application number
CY20171101065T
Other languages
English (en)
Inventor
Trevor Stitt
Esther Latres
Original Assignee
Regeneron Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44477626&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1119445(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Regeneron Pharmaceuticals, Inc. filed Critical Regeneron Pharmaceuticals, Inc.
Publication of CY1119445T1 publication Critical patent/CY1119445T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A61K49/16—Antibodies; Immunoglobulins; Fragments thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Abstract

Η παρούσα εφεύρεση παρέχει μεμονωμένα ή εξανθρωπισμένα αντισώματα ή τμήματα αυτών που προσδένουν αντιγόνα τα οποία συνδέονται συγκεκριμένα με τον Παράγοντα και τον Παράγοντα Διαφοροποίησης-8 (GDF8) και αποκλείουν την δραστηριότητα του GDF8. Τα αντισώματα και τμήματα αντισωμάτων της παρούσας εφεύρεσης μπορούν να χρησιμοποιηθούν σε θεραπευτικές μεθόδους για την θεραπεία καταστάσεων ή διαταραχών που ανακουφίζονται ή βελτιώνονται με την αναστολή του GDF8.
CY20171101065T 2010-05-26 2017-10-11 Αντισωματα εναντι του ανθρωπινου gdf8 CY1119445T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US34855910P 2010-05-26 2010-05-26
US37288210P 2010-08-12 2010-08-12
PCT/US2011/037837 WO2011150008A1 (en) 2010-05-26 2011-05-25 Antibodies to human gdf8

Publications (1)

Publication Number Publication Date
CY1119445T1 true CY1119445T1 (el) 2018-03-07

Family

ID=44477626

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20171101065T CY1119445T1 (el) 2010-05-26 2017-10-11 Αντισωματα εναντι του ανθρωπινου gdf8

Country Status (40)

Country Link
US (5) US8840894B2 (el)
EP (1) EP2576618B1 (el)
JP (1) JP5896993B2 (el)
KR (1) KR101859911B1 (el)
CN (1) CN102933602B (el)
AR (1) AR081221A1 (el)
AU (1) AU2011258342B2 (el)
BR (1) BR112012029986B1 (el)
CA (1) CA2800581C (el)
CL (1) CL2012003283A1 (el)
CO (1) CO6620013A2 (el)
CR (1) CR20120577A (el)
CY (1) CY1119445T1 (el)
DK (1) DK2576618T3 (el)
DO (1) DOP2012000295A (el)
EC (1) ECSP12012309A (el)
ES (1) ES2647389T3 (el)
GT (1) GT201200318A (el)
HR (1) HRP20171499T1 (el)
HU (1) HUE037140T2 (el)
IL (1) IL223003A (el)
JO (1) JO3340B1 (el)
LT (1) LT2576618T (el)
MX (2) MX2012013369A (el)
MY (1) MY157109A (el)
NI (1) NI201200171A (el)
NO (1) NO2576618T3 (el)
NZ (1) NZ603529A (el)
PE (1) PE20130226A1 (el)
PL (1) PL2576618T3 (el)
PT (1) PT2576618T (el)
RS (1) RS56368B1 (el)
RU (2) RU2567805C2 (el)
SG (2) SG185455A1 (el)
SI (1) SI2576618T1 (el)
TN (1) TN2012000555A1 (el)
TW (2) TW201701903A (el)
UY (1) UY33407A (el)
WO (1) WO2011150008A1 (el)
ZA (1) ZA201208525B (el)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2647846C (en) 2006-03-31 2016-06-21 Chugai Seiyaku Kabushiki Kaisha Methods for controlling blood pharmacokinetics of antibodies
EP4339294A2 (en) 2007-09-26 2024-03-20 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substitution in cdr
KR102057826B1 (ko) 2008-04-11 2019-12-20 추가이 세이야쿠 가부시키가이샤 복수 분자의 항원에 반복 결합하는 항원 결합 분자
JO3340B1 (ar) * 2010-05-26 2019-03-13 Regeneron Pharma مضادات حيوية لـعامل تمايز النمو 8 البشري
JP2013537425A (ja) 2010-08-16 2013-10-03 アムジエン・インコーポレーテツド ミオスタチンに結合するポリペプチド、組成物および方法
CA2819356C (en) 2010-11-30 2023-01-24 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly
SI2780368T1 (en) * 2011-11-14 2018-04-30 Regeneron Pharmaceuticals, Inc. INGREDIENTS AND PROCEDURES FOR INCREASING PURE MASS AND MICROWAVE WITH SPECIFIC ANTAGONISING OF GDF8 AND / OR ACTIVITY A
JO3820B1 (ar) 2012-05-03 2021-01-31 Regeneron Pharma أجسام مضادة بشرية لـ fel d1وطرق لاستخدامها
TW201823460A (zh) 2012-05-29 2018-07-01 美商再生元醫藥公司 生產細胞株增強子
US11236168B2 (en) 2012-08-24 2022-02-01 Chugai Seiyaku Kabushiki Kaisha Mouse FcγammaRII-specific Fc antibody
ES2776681T3 (es) 2012-08-24 2020-07-31 Chugai Pharmaceutical Co Ltd Variante de la región Fc específica de FcgammaRIIb
PL3564258T3 (pl) 2012-09-13 2021-10-25 Bristol-Myers Squibb Company Oparte na fibronektynie białka z domeną rusztowania, które wiążą się z miostatyną
EP3527219A1 (en) 2012-10-24 2019-08-21 Celgene Corporation Methods for treating anemia
AR095196A1 (es) 2013-03-15 2015-09-30 Regeneron Pharma Medio de cultivo celular libre de suero
CN110041427B (zh) 2013-03-15 2023-05-23 本质生命科学有限公司 抗铁调素抗体及其用途
EP3783017A1 (en) 2013-04-02 2021-02-24 Chugai Seiyaku Kabushiki Kaisha Fc region variant
PT2981822T (pt) 2013-05-06 2020-12-07 Scholar Rock Inc Composições e métodos para modulação do fator de crescimento
TW201920262A (zh) 2013-07-30 2019-06-01 美商再生元醫藥公司 抗活化素ａ之抗體及其用途
US10935554B2 (en) 2013-08-23 2021-03-02 Regeneron Pharmaceuticals, Inc. Diagnostic tests and methods for assessing safety, efficacy or outcome of allergen-specific immunotherapy (SIT)
US10323088B2 (en) 2014-09-22 2019-06-18 Intrinsic Lifesciences Llc Humanized anti-hepcidin antibodies and uses thereof
JP6706617B2 (ja) 2014-11-06 2020-06-10 スカラー ロック インコーポレイテッドＳｃｈｏｌａｒ Ｒｏｃｋ，Ｉｎｃ． 抗プロ／潜在型−ミオスタチン抗体およびその使用
MX2017006521A (es) * 2014-11-24 2017-08-09 Somalogic Inc Compuestos de acido nucleico para unirse al factor de diferenciacion de crecimiento 11.
EP3240804A4 (en) 2014-12-19 2019-01-09 Chugai Seiyaku Kabushiki Kaisha ANTI-MYOSTATIN ANTIBODIES, POLYPEPTIDES WITH DEVIANT FC REGIONS AND METHOD OF USE
CN114773470A (zh) 2015-02-05 2022-07-22 中外制药株式会社 包含离子浓度依赖性的抗原结合结构域的抗体，fc区变体，il-8-结合抗体及其应用
EP3256148A1 (en) 2015-02-12 2017-12-20 INSERM - Institut National de la Santé et de la Recherche Médicale Methods for predicting the responsiveness of a patient affected with malignant hematological disease to chemotherapy treatment and methods of treatment of such disease
JP6877357B2 (ja) 2015-04-15 2021-05-26 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Ｇｄｆ８阻害剤を用いて、強度及び機能を増加させる方法
TW202330904A (zh) 2015-08-04 2023-08-01 美商再生元醫藥公司 補充牛磺酸之細胞培養基及用法
CN113896790A (zh) 2015-09-15 2022-01-07 供石公司 抗-原肌生长抑制素/潜伏肌生长抑制素抗体及其用途
JP7141336B2 (ja) 2015-12-25 2022-09-22 中外製薬株式会社 抗ミオスタチン抗体および使用方法
CN115814077A (zh) 2016-01-08 2023-03-21 供石公司 抗-原肌生长抑制素/潜伏肌生长抑制素抗体及其使用方法
LT3368069T (lt) 2016-06-13 2020-12-10 Scholar Rock, Inc. Miostatino inhibitorių naudojimas, ir kombinuotas gydymas
CN109689099B (zh) 2016-08-05 2023-02-28 中外制药株式会社 用于预防或治疗il-8相关疾病的组合物
EP3504328A1 (en) 2016-08-24 2019-07-03 Regeneron Pharmaceuticals, Inc. Host cell protein modification
CN106770517A (zh) * 2016-12-16 2017-05-31 青岛科技大学 一种检测力竭运动后小鼠骨骼肌肌肉生长抑制素含量的方法
US11352417B2 (en) 2016-12-22 2022-06-07 Regeneron Pharmaceuticals, Inc. Method of treating an allergy with allergen-specific monoclonal antibodies
AU2018205270B2 (en) 2017-01-06 2022-08-11 Scholar Rock, Inc. Methods for treating metabolic diseases by inhibiting myostatin activation
WO2019010191A1 (en) 2017-07-06 2019-01-10 Regeneron Pharmaceuticals, Inc. CELL CULTURE METHOD FOR PRODUCING GLYCOPROTEIN
JP7321159B2 (ja) 2017-12-22 2023-08-04 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 薬剤生成物不純物を特性決定するためのシステム及び方法
WO2019129679A1 (en) 2017-12-29 2019-07-04 F. Hoffmann-La Roche Ag Method for improving vegf-receptor blocking selectivity of an anti-vegf antibody
MX2020008095A (es) 2018-01-31 2020-09-24 Regeneron Pharma Sistemas y métodos para caracterizar variantes de tamaño y carga de impurezas de productos farmacológicos.
TWI786265B (zh) 2018-02-02 2022-12-11 美商再生元醫藥公司 用於表徵蛋白質二聚合之系統及方法
JP2021514609A (ja) 2018-02-28 2021-06-17 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ウイルス混入物質を同定するためのシステムおよび方法
EP3758800A1 (en) 2018-03-01 2021-01-06 Regeneron Pharmaceuticals, Inc. Methods for altering body composition
TW202323813A (zh) 2018-03-19 2023-06-16 美商再生元醫藥公司 微晶片毛細管電泳分析及試劑
TW202016125A (zh) 2018-05-10 2020-05-01 美商再生元醫藥公司 用於定量及調節蛋白質黏度之系統與方法
JP2021535739A (ja) 2018-08-27 2021-12-23 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 下流精製でのラマン分光法の使用
EP3775926A1 (en) 2018-08-30 2021-02-17 Regeneron Pharmaceuticals, Inc. Methods for characterizing protein complexes
CN113195532A (zh) * 2018-12-18 2021-07-30 瑞泽恩制药公司 使用针对瘦素受体、gdf8和活化素a的拮抗剂增加体重和瘦肌肉质量的组合物和方法
CN117110492A (zh) 2019-01-16 2023-11-24 瑞泽恩制药公司 鉴别蛋白质中的游离巯基的方法
CA3135004A1 (en) 2019-05-13 2020-11-19 Regeneron Pharmaceuticals, Inc. Improved competitive ligand binding assays
US20220323937A1 (en) 2019-09-24 2022-10-13 Regeneron Pharmaceuticals, Inc. Systems and methods for chromatography use and regeneration
KR20220104797A (ko) 2019-11-25 2022-07-26 리제너론 파마슈티칼스 인코포레이티드 비수성 에멀전을 이용한 지속 방출 제형
WO2021142331A1 (en) * 2020-01-10 2021-07-15 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for modulation of genes associated with cardiac muscle disease
WO2021142269A1 (en) * 2020-01-10 2021-07-15 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for modulation of genes associated with muscle atrophy
IL294765B2 (en) 2020-01-21 2023-12-01 Regeneron Pharma Deglycosylation methods for electrophoresis of glycosylated proteins
US20220064591A1 (en) 2020-08-31 2022-03-03 Regeneron Pharmaceuticals, Inc. Asparagine feed strategies to improve cell culture performance and mitigate asparagine sequence variants
TW202237070A (zh) 2020-11-25 2022-10-01 美商再生元醫藥公司 使用非水性膜乳化之持續釋放調配物
EP4262757A1 (en) 2020-12-17 2023-10-25 Regeneron Pharmaceuticals, Inc. Fabrication of protein-encapsulating microgels
CA3202197A1 (en) 2021-01-20 2022-07-28 Reginald Smith Methods of improving protein titer in cell culture
CA3207883A1 (en) 2021-03-03 2022-09-09 Xiaobin Xu Systems and methods for quantifying and modifying protein viscosity
CA3211302A1 (en) 2021-03-26 2022-09-29 Ross Kenyon Methods and systems for developing mixing protocols
AU2022286340A1 (en) 2021-06-01 2024-01-04 Regeneron Pharmaceuticals, Inc. Microchip capillary electrophoresis assays and reagents
TW202326138A (zh) 2021-09-08 2023-07-01 美商再生元醫藥公司 用於定量抗體及其他含Ｆｃ蛋白之高通量及基於質譜之方法
WO2023044139A1 (en) 2021-09-20 2023-03-23 Regeneron Pharmaceuticals, Inc. Methods of controlling antibody heterogeneity
TW202323817A (zh) 2021-10-07 2023-06-16 美商再生元醫藥公司 Ｐｈ建模及控制之系統及方法
US20230110811A1 (en) 2021-10-07 2023-04-13 Regeneron Pharmaceuticals, Inc. pH METER CALIBRATION AND CORRECTION
TW202330104A (zh) 2021-10-26 2023-08-01 美商再生元醫藥公司 用於產生實驗室用水及分配不同溫度之實驗室用水的系統及方法
US20230296559A1 (en) 2022-03-18 2023-09-21 Regeneron Pharmaceuticals, Inc. Methods and systems for analyzing polypeptide variants
WO2024064842A1 (en) 2022-09-21 2024-03-28 Regeneron Pharmaceuticals, Inc. Methods of treating obesity, diabetes, and liver dysfunction

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
JP4124480B2 (ja) 1991-06-14 2008-07-23 ジェネンテック・インコーポレーテッド 免疫グロブリン変異体
US5994618A (en) 1997-02-05 1999-11-30 Johns Hopkins University School Of Medicine Growth differentiation factor-8 transgenic mice
EP0690873B1 (en) 1993-03-19 2003-06-11 The Johns Hopkins University School Of Medicine Growth differentiation factor-8
US6368597B1 (en) 1998-05-06 2002-04-09 Matamorphix, Inc. Methods of treating diabetes
SK722002A3 (en) 1999-07-20 2003-02-04 Pharmexa As Method for down-regulating GDF-8 activity
US7320789B2 (en) 2001-09-26 2008-01-22 Wyeth Antibody inhibitors of GDF-8 and uses thereof
US7261893B2 (en) 2002-10-22 2007-08-28 Wyeth Neutralizing antibodies against GDF-8 and uses therefor
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
EP2272864A3 (en) * 2002-12-20 2011-02-16 Amgen Inc. Binding agents which inhibit myostatin
AU2004245025A1 (en) 2003-06-02 2004-12-16 Wyeth Use of myostatin (GDF8) inhibitors in conjunction with corticosteroids for treating neuromuscular disorders
EP1699820A2 (en) 2003-12-31 2006-09-13 Schering-Plough Ltd. Neutralizing epitope-based growth enhancing vaccine
AU2005219441A1 (en) 2004-03-02 2005-09-15 Acceleron Pharma Inc. ALK7 and myostatin inhibitors and uses thereof
JP4695133B2 (ja) 2004-03-23 2011-06-08 イーライ リリー アンド カンパニー 抗ミオスタチン抗体
WO2005103081A2 (en) 2004-04-20 2005-11-03 Genmab A/S Human monoclonal antibodies against cd20
AU2005272646A1 (en) 2004-08-12 2006-02-23 Wyeth Combination therapy for diabetes, obesity, and cardiovascular diseases using GDF-8 inhibitors
NZ538097A (en) 2005-02-07 2006-07-28 Ovita Ltd Method and compositions for improving wound healing
EA015534B1 (ru) 2005-04-25 2011-08-30 Пфайзер Инк. Антитела к миостатину и способы их применения
ES2534760T3 (es) 2005-08-19 2015-04-28 Wyeth Llc Anticuerpos antagonistas contra GDF-8 y sus usos en el tratamiento de ELA y otros trastornos asociados con GDF-8
CA2624976A1 (en) 2005-10-06 2007-04-19 Eli Lilly And Company Anti-myostatin antibodies
UA92504C2 (en) 2005-10-12 2010-11-10 Эли Лилли Энд Компани Anti-myostatin monoclonal antibody
AU2006321906C1 (en) 2005-12-06 2014-01-16 Amgen Inc. Uses of myostatin antagonists
US7699146B1 (en) 2006-04-02 2010-04-20 Fox Factory, Inc. Suspension damper having inertia valve and user adjustable pressure-relief
PT2374818E (pt) 2006-06-02 2013-02-13 Regeneron Pharma Anticorpos com elevada afinidade para o receptor il-6 humano
CN101522707B (zh) * 2006-08-03 2013-08-28 莫约斯汀医疗有限公司 肌肉生长抑制素拮抗剂
CA2661836A1 (en) * 2006-09-05 2008-03-13 Eli Lilly And Company Anti-myostatin antibodies
CL2007002567A1 (es) 2006-09-08 2008-02-01 Amgen Inc Proteinas aisladas de enlace a activina a humana.
CN100586476C (zh) * 2006-10-13 2010-02-03 中国人民解放军第四军医大学 一种Myostatin特异性抗体的治疗性疫苗及其制备方法
TW201718635A (zh) 2007-03-06 2017-06-01 安美基公司 變異之活動素受體多肽及其用途
PE20091163A1 (es) 2007-11-01 2009-08-09 Wyeth Corp Anticuerpos para gdf8
WO2009059943A1 (en) 2007-11-05 2009-05-14 Novartis Ag 4-benzylamino-1-carboxyacyl-piperidine derivatives as cetp inhibitors useful for the treatment of diseases such as hyperlipidemia or arteriosclerosis
TWI626945B (zh) 2008-08-14 2018-06-21 艾瑟勒朗法瑪公司 使用ｇｄｆ阱以增加紅血球水平
TW201029662A (en) 2008-12-19 2010-08-16 Glaxo Group Ltd Novel antigen binding proteins
NO2424895T3 (el) 2009-04-27 2018-02-03
WO2010151792A1 (en) 2009-06-26 2010-12-29 Regeneron Pharmaceuticals, Inc. Readily isolated bispecific antibodies with native immunoglobulin format
JO3340B1 (ar) 2010-05-26 2019-03-13 Regeneron Pharma مضادات حيوية لـعامل تمايز النمو 8 البشري
SI2780368T1 (en) 2011-11-14 2018-04-30 Regeneron Pharmaceuticals, Inc. INGREDIENTS AND PROCEDURES FOR INCREASING PURE MASS AND MICROWAVE WITH SPECIFIC ANTAGONISING OF GDF8 AND / OR ACTIVITY A
TW201920262A (zh) 2013-07-30 2019-06-01 美商再生元醫藥公司 抗活化素ａ之抗體及其用途

Also Published As

Publication number Publication date
JP2013528608A (ja) 2013-07-11
DK2576618T3 (en) 2017-10-02
PL2576618T3 (pl) 2018-01-31
US20190023777A1 (en) 2019-01-24
AU2011258342B2 (en) 2016-04-21
US20110293630A1 (en) 2011-12-01
HUE037140T2 (hu) 2018-08-28
US20160340421A1 (en) 2016-11-24
MY157109A (en) 2016-05-13
NO2576618T3 (el) 2018-01-13
BR112012029986A2 (el) 2017-08-22
CA2800581A1 (en) 2011-12-01
EP2576618A1 (en) 2013-04-10
US20240067712A1 (en) 2024-02-29
ECSP12012309A (es) 2012-12-28
TWI602917B (zh) 2017-10-21
TN2012000555A1 (en) 2014-04-01
DOP2012000295A (es) 2013-04-15
TW201201838A (en) 2012-01-16
CR20120577A (es) 2013-03-04
CN102933602A (zh) 2013-02-13
US20140356369A1 (en) 2014-12-04
US8840894B2 (en) 2014-09-23
KR20130109981A (ko) 2013-10-08
TW201701903A (zh) 2017-01-16
AU2011258342A1 (en) 2012-12-20
RU2012156938A (ru) 2014-07-10
PT2576618T (pt) 2017-10-23
RS56368B1 (sr) 2017-12-29
WO2011150008A1 (en) 2011-12-01
SG10201504092TA (en) 2015-06-29
US9260515B2 (en) 2016-02-16
RU2015143242A (ru) 2018-12-28
ES2647389T3 (es) 2017-12-21
UY33407A (es) 2011-12-01
NI201200171A (es) 2013-04-15
EP2576618B1 (en) 2017-08-16
US9890212B2 (en) 2018-02-13
CA2800581C (en) 2019-04-09
JO3340B1 (ar) 2019-03-13
HRP20171499T1 (hr) 2017-11-17
RU2015143242A3 (el) 2019-05-21
SI2576618T1 (sl) 2017-10-30
MX2012013369A (es) 2013-02-11
CO6620013A2 (es) 2013-02-15
CN102933602B (zh) 2016-08-03
IL223003A0 (en) 2013-02-03
AR081221A1 (es) 2012-07-04
ZA201208525B (en) 2013-07-31
BR112012029986B1 (pt) 2022-05-24
LT2576618T (lt) 2017-10-25
PE20130226A1 (es) 2013-03-15
CL2012003283A1 (es) 2013-01-25
NZ603529A (en) 2015-07-31
IL223003A (en) 2017-12-31
KR101859911B1 (ko) 2018-05-21
JP5896993B2 (ja) 2016-03-30
MX357145B (es) 2018-06-28
GT201200318A (es) 2014-01-27
SG185455A1 (en) 2012-12-28
RU2710156C2 (ru) 2019-12-24
RU2567805C2 (ru) 2015-11-10

Similar Documents

Publication Publication Date Title
CY1119445T1 (el) Αντισωματα εναντι του ανθρωπινου gdf8
CY1122593T1 (el) Αντισωματα εναντι-cd40 και χρησεις αυτων
CY1120471T1 (el) Αντισωματα κατα του cd70
CY1124771T1 (el) Αντισωματα εναντι-σορτιλiνης και μεθοδοι χρησης αυτων
CY1120359T1 (el) Σταθερες φαρμακοτεχνικες μορφες αντισωματων εναντι ανθρωπινου υποδοχεα pd-1 προγραμματισμενου θανατου και σχετικες θεραπειες
CY1122840T1 (el) Ανθρωποποιημενα ή χιμαιρικα αντισωματα cd3
CY1120398T1 (el) Ανθρωποποιημενα αντισωματα που αναγνωριζουν αλφα-συνουκλεϊνη
PH12018501220A1 (en) Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof
CY1119994T1 (el) Συνθεσεις και μεθοδοι για αυξηση της μυϊκης μαζας και της μυϊκης δυναμης ανταγωνιζοντας ειδικα ton gdf8 και/ή την ακτιβινη α
CY1121538T1 (el) Μονοκλωνικα αντισωματα εναντι του αναστολεα του μονοπατιου ιστικου παραγοντα (tfpi)
UA116873C2 (uk) Антитіло, яке зв'язується з ox40
EA201391175A1 (ru) Гетеродимерные иммуноглобулины
BR112015006060A2 (pt) agentes de ligação kir3dl2
NZ626242A (en) Anti-asic1 antibodies and uses thereof
EA201591191A1 (ru) Антитела против ntb-a и связанные с ними композиции и способы
GB201109238D0 (en) Antibodies
CY1120877T1 (el) Συνθεσεις και μεθοδοι για την αντιμετωπιση της κοιλιοκακης
EA201400447A1 (ru) АНТИТЕЛА К CD1d
MX2014013678A (es) Agentes para neutralizacion de influenza.
CY1123519T1 (el) Ανθρωπινα μονοκλωνικα αντισωματα εξουδετερωσης il-ß
MX2015008534A (es) COMPOSICIONES DE ANTICUERPO ANTI-INTEGRINA ß1 Y METODOS DE USO DE LAS MISMAS.
MX2014001766A (es) Anticuerpos de neuregulina y sus usos.
CY1120074T1 (el) Συνθεσεις για την θεραπευτικη αγωγη της ρευματοειδους αρθριτιδας και μεθοδοι χρησης αυτων
UA112521C2 (uk) Антитіло проти gdf8 людини
TR201905240T4 (tr) LIV-1'e hümanize edilmiş antikorlar ve bunların kanserin tedavisinde kullanımı.